We know that the success of your research requires the highest-quality reagents. Since our founding in 1993 we been determined to provide the highest-quality peptides and superior customer service. It’s because of this that we are able to feature over 600 catalogue peptides at the same level of quality as our customized products. In addition, our customers have direct access to our science team ensuring that they receive exactly what they need. We strive to be more than just a peptide supplier and our return business and frequent mentions in published research show that we have succeeded in our aims. Our goal is to help you achieve the best results by providing the highest-quality peptides with the best service available.
News

November 18, 2010 — Lonza and California Peptide Research, Inc. (CPRI) have entered into a strategic collaboration to more effectively serve customers requesting peptide manufacturing and development services.

More »

April 15, 2010 — California Peptide Research, Inc. (CPRI) announced today it has been awarded a blanket purchase agreement (BPA) by the National Institutes of Health (NIH) for its peptide products and consulting services. The BPA is effective April 15, 2010 and has no purchase limit for the NIH research community.

More »

April 1, 2010 — California Peptide Research, Inc. (CPRI) announces the introduction of HFIP (hexafluoroisopropanol) treated beta amyloids to its existing catalog of neuropeptides. The new HFIP treated beta amyloids will be offered in the 1-40 and 1-42 variants in 1.0 mg and 0.5 mg quantities.

More »